Hard to handicp the upside. The science guys can't really get a read on the drug but most biotech guys are involved just from a risk reward perspective. Assigning 60-40 chance of good data with Maximum downside in the low 4s, guys just want to be in it in case it pulls an srpt which is a similar situation. Hard to handicap drug from a science perspective but big upside if the data is ok....if it dips, we will see guys buy low 4 level because more data will be released in a few months, this is just an early peek...
Market Data 
Markets 
AI
